





## Comprehensive antimicrobial susceptibility testing (AST) for multidrug-resistant (MDR) Gram negative infections on a single, automated platform

Treating multidrug-resistant infections and monitoring emergent multidrug resistance is more important now than ever. Our new Thermo Scientific™ Sensititre™ plates provide clinicians with gold standard-level<sup>1</sup>, accurate definitive minimum inhibitory concentration (MIC) results to guide optimal treatment decisions when it matters most.

AST for Gram negative and, even more serious, MDR infections doesn't have to be complicated or labor-intensive. Reduce offline testing, improve workflow and provide accurate MIC results to optimally guide the best therapeutic decisions with Sensititre AST plates in off-the shelf, standard formats, as well as:

 The latest antimicrobials, including sulbactam/durlobactam, a new therapeutic option for bacterial pneumonia caused by *Acinetobacter baumannii*, for comprehensive AST using second-line MDRO therapies. In fact, the Sensititre System is the only FDA-cleared automated susceptibility platform assay for sulbactam/durlobactam susceptibility testing of *Acinetobacter baumannii-calcoaceticus* complex isolates

 Expanded dilution ranges for Gram negative organisms to better detect emerging resistance, and a variety of manual and automated read options

9 out of top 10 hospitals\*\* use Thermo Scientific™ Sensititre™ Complete Automated AST System

\*\*US News and World Report. America's Best Hospitals:

The 2023-2024 Honor Roll and Overview. Information on file.


\* For research use only. Not for use in diagnostic procedures.

1. Gram negative anaerobe susceptibility testing in clinical isolates using Sensititre and Etest methods. C. Hughes, C. Ashurst-Smith, J.K. Ferguson. Pathology Volume 50, Issue 4, June 2018.

### Key antimicrobials on new Sensititre plates for multidrug-resistant (MDR) infections:

Ceftazidime/Avibactam	MDRGN4F MDRGNX4F*
Ceftolozane/Tazobactam	MDRGN4F MDRGNX4F*
Colistin	MDRGNX4F*
Eravacycline	MDRGN4F MDRGNX4F*
Fosfomycin	MDRGNX4F*
Imipenem/Relebactam	MDRGN4F MDRGNX4F*
Meropenem	MDRGN4F MDRGNX4F*
Meropenem/Vaborbactam	MDRGN4F MDRGNX4F*
Omadacycline	MDRGN4F MDRGNX4F*
Plazomicin	MDRGN4F MDRGNX4F*
Sulbactam/durlobactam	MDRGN4F MDRGNX4F*

# Sensititre Gram Negative MDRGN4F AST Plate w/ Sulbactam/Durlobactam




## Antimicrobics

<b>AMI</b>	Amikacin
<b>CZA</b>	Ceftazidime / Avibactam Constant 4
<b>C/T</b>	Ceftolozane / Tazobactam Constant 4
<b>DLX</b>	Delafloxacin
<b>ERV</b>	Eravacycline
<b>IMI</b>	Imipenem
<b>IMR</b>	Imipenem / Relebactam Constant 4
<b>LEVO</b>	Levofloxacin
<b>MERO</b>	Meropenem
<b>MEV</b>	Meropenem / Vaborbactam Constant 8
<b>NEG</b>	Negative Control
<b>OMC</b>	Omadacycline
<b>PLZ</b>	Plazomicin
<b>POS</b>	Positive Control
<b>SUD</b>	Sulbactam / Durlobactam Constant 4

“Current research has demonstrated that the spread of multi-drug resistant organisms are largely driven by the physical movement of patients. As a result, hospitals that have never seen a pan-resistant *Acinetobacter baumannii* or pan beta-lactam-resistant *Pseudomonas aeruginosa* are only one admission away from seeing their first case.”

Dr. James McKinnell, Associate Professor of Medicine,  
David Geffen School of Medicine, University of California, Los Angeles

# Sensititre Gram Negative MDRGN4XF AST Plate\* w/ Sulbactam/Durlobactam



## Antimicrobics

<b>CZA</b>	Ceftazidime / Avibactam Constant 4
<b>C/T</b>	Ceftolozane / Tazobactam Constant 4
<b>COL</b>	Colistin
<b>DLX</b>	Delafloxacin
<b>ERV</b>	Eravacycline
<b>FOS+</b>	Fosfomycin+ glucose-6-phosphate
<b>IMI</b>	Imipenem
<b>IMR</b>	Imipenem / Relebactam Constant 4
<b>MERO</b>	Meropenem
<b>MEV</b>	Meropenem / Vaborbactam Constant 8
<b>OMC</b>	Omadacycline
<b>PLZ</b>	Plazomicin sulfate
<b>POS</b>	Positive Control
<b>SUD</b>	Sulbactam / Durlobactam Constant 4

\* For research use only. Not for use in diagnostic procedures.

“In my practice, I depend on susceptibility testing for novel antibiotics for management of highly resistant MDRO infections. I cannot reliably predict which of these agents are going to be microbiologically active for my patients and my lab certainly does not want to do one-by-one manual testing for all of these combinations so that I can make my treatment decisions.”

Dr. James McKinnell, Associate Professor of Medicine,  
David Geffen School of Medicine, University of California, Los Angeles

Related Products	Quantity	Part No.
Sensititre Gram Negative MDRGN4F AST Plate	10/box	MDRGN4F
Sensititre Gram Negative MDRGNX4F AST Plate w/ Colistin and Fosfomycin	10/box	MDRGNX4F*
Thermo Scientific™ Sensititre™ ARIS HiQ™ AST System	each	V4000
Thermo Scientific™ Sensititre™ OptiRead™ Automated Fluorometric Plate Reading System	each	V3030
Thermo Scientific™ Sensititre™ Vizion™ Digital MIC Viewing System	each	V2021
Thermo Scientific™ Sensititre AIM™ Automated Inoculation Delivery System	each	V3020
Mueller Hinton Broth	11 mL; 100/box	T3462
Demineralized Water	5 mL; 100/box	T3339

\*For research use only. Not for use in diagnostic procedures.



**█** To learn more about our complete range of antimicrobial susceptibility testing solutions, visit [thermofisher.com/AST](https://thermofisher.com/AST)

Products are distributed globally so uses, applications, and availability of product in each country depend on local regulatory marketing authorization status.

© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. **LT3051B June 2024**